Dyne Therapeutics enters underwriting agreement for 18.3M common stock shares
Dyne Therapeutics, Inc. entered an underwriting agreement with Morgan Stanley & Co. LLC and Jefferies LLC to sell 18.3 million shares of common stock, with up to 2.745 million additional shares available for purchase by underwriters.
View filing at SEC.gov →